Microscopic Polyangiitis (MPA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 40 Published: March 31, 2022 Report Code: GMDGDHC22005IDB

Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune, necrotizing, small-vessel vasculitis without clinical or pathological evidence of necrotizing granulomatous inflammation. The signs and symptoms of microscopic polyangiitis may resemble those of granulomatosis with polyangiitis (GPA) (another form of small-vessel vasculitis) but lack the significant upper respiratory tract involvement frequently seen in people affected by GPA.

The Microscopic Polyangiitis drugs in development market research report provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and the molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Microscopic Polyangiitis and features dormant and discontinued projects.

What are the key targets in the Microscopic Polyangiitis pipeline products market?

The key targets in the Microscopic Polyangiitis pipeline products market are Cells Expressing B Lymphocyte Antigen CD20 and Complement C5.

Microscopic Polyangiitis Pipeline Products Analysis Market by Targets

Microscopic Polyangiitis Pipeline Products Analysis Market by TargetsFor more target insights, download a free report sample

What are the key mechanisms of action in the Microscopic Polyangiitis pipeline products market?

The key mechanisms of action in the Microscopic Polyangiitis pipeline products market are Cytotoxic to Cells Expressing B Lymphocyte Antigen CD20 and Complement C5 Inhibitor.

Microscopic Polyangiitis Pipeline Products Market Analysis by Mechanism of Actions

Microscopic Polyangiitis Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

What are the key routes of administration in the Microscopic Polyangiitis pipeline products market?

The key routes of administration in the Microscopic Polyangiitis pipeline products market are intravenous, parenteral, and subcutaneous.

Microscopic Polyangiitis Pipeline Products Market Analysis by Routes of Administration

Microscopic Polyangiitis Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

What are the different molecule types in the Microscopic Polyangiitis pipeline products market?

The different molecule types in the Microscopic Polyangiitis pipeline products market are monoclonal antibody and antibody.

Microscopic Polyangiitis Pipeline Products Market Analysis by Molecule Type

Microscopic Polyangiitis Pipeline Products Market Analysis by Molecule TypeTo know more about molecule types, download a free report sample

Which are the major companies in the Microscopic Polyangiitis pipeline products market?

The major companies in the Microscopic Polyangiitis pipeline products market are Biogen Inc, InflaRx NV, Mabion SA, Nanolek, Pharmapraxis, and Teijin Pharma Ltd.

Microscopic Polyangiitis Pipeline Products Market Analysis by Companies

Microscopic Polyangiitis Pipeline Products Market Analysis by CompaniesTo know more about major companies, download a free report sample

Market Report Scope

Key targets Cells Expressing B Lymphocyte Antigen CD20 and Complement C5
Key mechanism of action Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20 and Complement C5 Inhibitor
Key routes of administration Intravenous, Parenteral, and Subcutaneous
Molecule type Monoclonal Antibody and Antibody
Major companies Biogen Inc, InflaRx NV, Mabion SA, Nanolek, Pharmapraxis, and Teijin Pharma Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis ((MPA) Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

Biogen Inc

InflaRx NV

Mabion SA

Nanolek

Pharmapraxis

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Microscopic Polyangiitis (MPA) – Overview

Microscopic Polyangiitis (MPA) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Microscopic Polyangiitis (MPA) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Microscopic Polyangiitis (MPA) – Companies Involved in Therapeutics Development

Biogen Inc

InflaRx NV

Mabion SA

Nanolek

Pharmapraxis

Teijin Pharma Ltd

Microscopic Polyangiitis (MPA) – Drug Profiles

immune globulin (human) – Drug Profile

Product Description

Mechanism Of Action

History of Events

rituximab – Drug Profile

Product Description

Mechanism Of Action

History of Events

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

rituximab biosimilar – Drug Profile

Product Description

Mechanism Of Action

vilobelimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Microscopic Polyangiitis (MPA) – Dormant Projects

Microscopic Polyangiitis (MPA) – Discontinued Products

Microscopic Polyangiitis (MPA) – Product Development Milestones

Featured News & Press Releases

Jan 30, 2020: The CHMP recommended extensions of indication for MabThera

Sep 30, 2019: Roche’s Rituxan secures approval for first paediatric indication

Jun 12, 2019: FDA grants priority review to Genentech’s Rituxan (Rituximab) in children with two rare blood vessel disorders

Nov 15, 2018: Roche receives positive CHMP opinion to expand MabThera for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

Mar 22, 2013: Roche Receives CHMP Positive Opinion For MabThera

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Microscopic Polyangiitis (MPA), 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Microscopic Polyangiitis (MPA) – Pipeline by Biogen Inc, 2022

Microscopic Polyangiitis (MPA) – Pipeline by InflaRx NV, 2022

Microscopic Polyangiitis (MPA) – Pipeline by Mabion SA, 2022

Microscopic Polyangiitis (MPA) – Pipeline by Nanolek, 2022

Microscopic Polyangiitis (MPA) – Pipeline by Pharmapraxis, 2022

Microscopic Polyangiitis (MPA) – Pipeline by Teijin Pharma Ltd, 2022

Microscopic Polyangiitis (MPA) – Dormant Projects, 2022

Microscopic Polyangiitis (MPA) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Microscopic Polyangiitis (MPA), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.